Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Table 2

Summary of findings and strength of evidence.

Outcome	Studies (patients)	Mean differences/relative effect (95% CI)	I^2	Certainty of the evidence
HbA1c (%)	3 (2066)	MD: −0.40 (−0.54, −0.25)	44%	Low^1,2
FBG (mmol/L)	3 (2066)	MD: −0.17 (−0.31, −0.04)	0	Low^1,2
PBG (mmol/L)	2 (1609)	MD: −0.32 (−0.49, −0.14)	44%	Low^1,2
Bodyweight (kg)	3 (2066)	MD: −0.26 (−0.93, 0.42)	77%	Very Low^1,2,3
Adverse events	3 (2068)	RR: 1.03 (0.98, 1.09)	0	Low^1,2
Hypoglycemia	2 (1605)	RR: 1.38 (0.96, 1.98)	35%	Low^1,2
Urinary tract infections	2 (1249)	RR: 0.98 (0.60, 1.58)	0	Moderate^2
Gastrointestinal events	2 (1249)	RR: 1.62 (1.37, 1.93)	0	Moderate^2

HbA1c: glycated haemoglobin, FBG: fasting blood glucose, PBG: postprandial blood glucose, CI: confidence interval, RR, risk ratio; MD, mean difference. ¹Study limitations for one of the trail lacked of blinding. ²Strongly suspected publication bias for all the trials were sponsored by companies. ³Inconsistency for substantial heterogeneity.